The Food and Drug Administration announced on Monday, Nov. 9, that every GLP-1 medication sold in the United States, including Ozempic, must now feature a warning regarding a rare eye condition capable of producing sudden and permanent blindness, affecting millions of American patients taking Ozempic.
The condition, known as nonarteritic anterior ischemic optic neuropathy, or NAION, cuts off blood flow to the optic nerve. It usually steals sight in one eye without any pain. The regulatory update applies to Ozempic, Wegovy, Mounjaro, Zepbound, and the rest of the medication class.
The FDA called the condition rare after reviewing 126 clinical trials involving more than 134,000 patients. The agency found about 6.4 cases for every 100,000 people taking a GLP-1 for a year. That compares with about 3.8 cases among people taking a placebo or another diabetes drug.
How NAION Affects GLP-1 Patients
NAION functions essentially as a stroke in the eye. A sudden reduction in circulation to the front of the optic nerve inflicts damage upon the pathway responsible for transmitting visual data to the brain. There is no known treatment to reverse the resulting vision loss.
If an individual develops NAION in one eye, the probability of eventually experiencing the same condition in the opposite eye increases. Symptoms include sudden vision loss in one eye, blurry or hazy spots, blind spots, tunnel vision, and colors that look washed out. Many people first notice the change when they wake up.
Because the condition does not hurt, it is easy to dismiss as tired eyes. That exact dynamic is why the FDA wants patients to recognize the warning signs early.
FDA Warning Covers Several GLP-1 Medications
The new FDA warning covers semaglutide drugs Ozempic, Wegovy, and Rybelsus. It also applies to tirzepatide drugs Mounjaro and Zepbound, plus Trulicity, Victoza, Saxenda, and Foundayo. Sanofi’s Soliqua is included as well, with the FDA reporting that cases have emerged with every GLP-1 currently on the market.
Scale matters when evaluating the risk across the country. CVS Health estimates more than 137 million U.S. adults are medically eligible for semaglutide. A risk that remains rare for any individual person still accumulates into real cases across a population of that magnitude.
NAION Risk Factors Affect Certain Communities
Diabetes, high blood pressure, sleep apnea, kidney disease, anemia, and smoking history are recognized as established risk factors for NAION. Many of those overlap directly with the very conditions GLP-1 medications are prescribed to treat.
Because of this overlap, particular demographic groups find themselves right at the center of the recent regulatory change, given that Black Americans report higher proportions of hypertension and diabetes relative to national averages and frequently utilize these pharmaceutical treatments to address both issues.
Rather than panicking, individuals undergoing these treatments should view the advisory as an incentive to thoroughly memorize the associated symptoms, following a 2025 decision by European health authorities to categorize NAION as an infrequent semaglutide adverse reaction expected to impact roughly one out of every 10,000 individuals undergoing treatment for a minimum of twelve months.
Manufacturers Respond to FDA Findings
The FDA said that a direct causal link has not been proven. The agency could not identify a mechanism for how the drugs might raise the risk and said that patient reports remain hard to interpret because NAION risk factors overlap with conditions common in people taking these medications.
Novo Nordisk, which manufactures Ozempic and Wegovy, said that the data do not show the drugs cause NAION and that the company remains confident in their benefits. The manufacturer of Zepbound and Mounjaro, Eli Lilly, said that the recent FDA alert fails to reference specific data concerning its products and indicated that it is currently reviewing the modification.
A consensus opinion published in August by two leading eye medicine groups said that the overall risk for GLP-1 users remains low. In the interim, legal actions have been initiated against both Eli Lilly and Novo Nordisk by numerous American consumers asserting a complete lack of prior disclosure regarding this danger.
Medical Advice on Stopping Treatment
Patients should not stop taking their medication on their own accord. The FDA advises anyone who notices sudden vision changes to contact a health care professional right away.
If NAION is confirmed, the agency recommends prescribers consider stopping the GLP-1 treatment unless the benefits clearly outweigh the risks. For everyone else, the decision regarding continued use should be made alongside a doctor who understands the patient’s full health history.